Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 25-32

  Pignata, S ^a   Daniele, B ^b   Gallo, C ^c   De Vivo, R ^a   Monfardini, S ^b   Perrone, F ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Dipartimento di Scienze Ambientali   (Italy)

^c CNR   (Italy)

Author keywords

Androgen receptor; Androgens; Endocrine treatment; Hepatocellular carcinoma; Oestrogen; Oestrogen receptor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BUSERELIN; CYPROTERONE ACETATE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUTAMIDE; GESTAGEN; KETOCONAZOLE; MEGESTROL; NILUTAMIDE; SEX HORMONE; TAMOXIFEN; TRIPTORELIN;

CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER REGENERATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; GONADAL STEROID HORMONES; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASMS, HORMONE-DEPENDENT; RANDOMIZED CONTROLLED TRIALS; RATS; RATS, WISTAR; RECEPTORS, ESTROGEN;

EID: 0031889197     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00317-1     Document Type: Review

References (80)

1. Nagasue N, Ogawa Y, Yukaya H, Ohta N, Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology 1985, 88, 768-772.
2. Guechot J, Peigney Ballet F, Vaubourdolle M, Giboudeau J, Poupon R. Sex hormone imbalance in male cirrhotic patients with and without hepatocellular carcinoma. Cancer 1988, 62, 760-762.
3. Eagon PK, Elm MS, Stafford EA, Porter LE. Androgen receptor in human liver: characterization and quantitation in normal and diseased liver. Hepatology 1994, 19, 92-100.
4. Porter LE, Elm MS, Van Thiel DH, Eagon PK. Hepatic estrogen receptor in human liver disease. Gastroenterology 1987, 92, 735-745.
5. Francavilla A, Di Leo A, Eagon PK. Regenerating rat liver: correlation between estrogen receptor localization and deoxyribonucleic acid synthesis. Gastroenterology 1984, 86, 562-567.
6. Eagon PK, Porter LE, Francavilla A, et al. Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 1985, 5, 59-69.
7. Francavilla A, Eagon PK, Di Leo A, et al. Sex hormone related functions in regenerating male rat liver. Gastroenterology 1986, 91, 1263-1270.
8. Francavilla A, Polimeno L, DiLeo A, et ai. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989, 9, 614-620.
9. Ni N, Yager JD. Comitogenic effects of estrogens on DNA synthesis induced by various growth fac:ors in cultured female rat hepatocytes. Hepatology 1994, 19, 183-192.
10. Kahn D, Makowka L, Zeng P, Murase N, Starzl TE, Van Thiel DH. Estrogen and androgen receptors in the liver after orthotopic liver transplantation. Transplant Proc 1988, 20, 494-497.
11. Van Thiel DH, Stauber R, Garder JS, Francavilla A. Hepatic regeneration. Effects of age, sex hormone status, prolactin and cyclosporin. Dig Dis Sei 1991, 36, 1309-1312.
12. Kahn D, Swanas G, Eagon PK, et al. Liver regeneration in rats treated with the antiandrogen flutamide. J Invest Surg 1988, 1, 133-138.
13. Kahn D, Swanas G, Eagon PK, et al. Effect of an antiandrogenic H2-receptor antagonist on hepatic regeneration in rats. J Lab Clin Med 1988, 112, 232-239.
14. Yager JD, Yager R. Oral contraceptive sieroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980,40, 3680-3685.
15. Camerron RG, Imaida K, Tsuda H, Ito M. Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res 1982, 42, 2426-2428.
16. Yager JD, Zurlo J, Ni N. Sex hormones and tumor promotion in liver. Proc Soc Exp Biol Med 1991, 198, 667-674.
17. Mayol X, Meal GE, Davies R, Romero A, Domingo J. Ethinyl estradiol-induced cell proliferation in rat liver. Involvement of specific populations of hepatocytes. Carcinogenesis 1992, 13, 2381-2388.
18. Toh YC. Effect of neonatal castration on liver rumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis 1981, 2, 1219-1221.
19. Moore MR, Drinkwater NR, Miller EC, Miller JA. Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 1981, 41, 1585-1593.
20. Reuber MD. Influence of hormones on N-2-fluoroenyldiacetamide-induced hyperplastic hepatic nodules in rats. J Natl Cancer Inst 1969, 43, 445-452.
21. Matsuura B, Taniguki Y, Ohta Y. Effecl of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J Hepatol 1994, 21, 187-193.
22. Ostrowski JL, Ingleton PM, Underwood JCE, Pearsons MA. Increased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. A possible correlation with liver tumor development. Gastroenterology 1988, 94, 1193-1200.
23. Kemp CJ, Leary CN, Drinkwater NR. Promotion of murine hepatocarcinogenesis by testosterone :.s androgen receptordependent but not cell autonomous. Proc Natl Acad Sei USA 1989,86, 7505-7509.
24. Shaw 1C, Jones HB. Mechanisms of non-genotoxic carcinogens. Trends Pharmaceut Sei 1994, IS, 89-93.
25. Reddy JK, Lalwani ND. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers in humans. CRC Crit Rev Toxicol 1982, 12, 1-58.
26. Dirven HAAM, Theuws JIG, Jongeneelen FJ, Bos RP. Nonmutagenicity of 4 metabolites of di(2-ethylhexyl)phthalate (DEHP) and 3 structurally related derivatives of di(2-ethylexyl)adipate (DEHA) in the Salmonella mutagenicity assay. Mutat Res 1991, 260, 1303-1308.
27. Eagon PK, Elm MS, Epley MJ, Shinozuka H, KN Rao. Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterology 1996, 110, 1199-1207.
28. Eagon PK, Chandar N, Epley MJ, Elm MS, Brady EP, Rao KN. Di(2-ethylexyl)phthalate-induced changes in liver estrogen metabolism and hyperplasia. Int J Cancer 1994, 58, 736-743.
29. Sumi C, Yokoro K, Matsushima R. Induction of hepatic tumors by diethylstilbestrol alone or in synergism with N-nitrosoburylureain castrated male WF rats. J Nad Cancer Inst 1983, 70, 937-942.
30. Wanless IR, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982, 46, 313-320.
31. Coe JE, Ishak Kl, Ross MJ. Estrogen induction of hepatocellular carcinoma in Armenian Hamsters. Hepatology 1990, 11, 570-577.
32. Tanigawa K. Experimental studies on hepatocarcinogenesis of synthetic estrogen and progesterone, with special reference to progression and biological characteristics of the developed hepatocellular carcinoma. Acta Hepatol Jpn 1989, 985-944.
33. Katoh H. Kinetics and role of DNA adducts in estrogen induced hepatocarcinogenesis in rats. Mie Med J 1994, 44, 67-77.
34. Shecter J, Weiner R. Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitaries of Fisher 344 and Sprague-Dawley rats. Endocrinology 1991, 129,2400-2408.
35. Shinomura M, Higashi S, Mizumoto R. P-analysis of DNA adducts in rats during ethynilestradiol induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct formation. Jpn J Cancer Res 1992, 83, 438-144.
36. Machishi H. Activation of rat c-H-ras oncogene during estrogen induced hepatocarcinogenesis. Mie-Igaku 1993, 37, 127-135.
37. Machishi H, Higashi S, Hibasami H, Nakashima K, Kawarada Y, Mizumoto R. Role of activation of ornithine decarboxylase and DNA synthesis on ethynilestradiol-induced hepatocarcinogenesis. Carcinogenesis 1995, 16, 2965-2971.
38. Shy YE, Yager JD. Regulation of rat hepatocyte epidermal growth factor receptor by the liver promoter ethynil estradiol. Carcinogenesis 1990, 11, 1003-1009.
39. Ni N, Yager JD. Comitogenic effects of estrogens on DNA synthesis induced by various growth factors in cultured female rat hepatocytes. Hepatology 1994, 19, 183-192.
40. Ogawa T, Higashi S, Kawarada Y, Mizumoto R. Role of reactive oxygen in synthetic estrogen induction of hepatocellular carcinomas in rats and preventive effect of vitamins. Carcinogenesis 1995, 16, 831-836.
41. Baum JK, Holtz F, Bookstein JJ, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973, U, 926-929.
42. Stauffer JQ, Lapinski MW, Harold DJ, Myers JK. Focal nodular hyperplasia of the liver. Am J Clin Pathol 1975, 83, 301-306.
43. Mays ET, Christopherson WM, Barrows GH. Focal nodular hyperplasia of the liver. Am J Clin Pathol 1974, 61, 735-746.
44. Neuberger J, Portman B, Nunnerley HB, Laws JW, Davis M, Williams R. Oral contraceptives associated liver tumors: occurrence of malignancy and difficulties in the diagnosis. Lancet 1980, i, 336-345.
45. Porter LE, Van Thiel DH, Eagon PK. Estrogens and progestins as tumor inducers. Semin Liver Dis 1987, 7, 24-31.
46. Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995, 19, 13-18.
47. Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet 1991, 173, 426-431.
48. Edmondson HA, Reynolds TB, Henderson B, Benton N. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977, 86, 180-182.
49. La Vecchia C, Negri E, Parazzini F. Oral contraceptives and primary liver cancer. Br J Cancer 1989, 59, 460-61.
50. Tavani A, Negri E, Parazzini F, Franceschi S, LaVecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993, 67, 635-637.
51. Bernstein MS, Hunter RL, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia. N Engl J Med 1971, 284, 1135-1136.
52. Johnson FL, Feagler JR, Lerner KG. Association of androgenic anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1992, 2, 1273-1276.
53. Ming-Whei Y, Chien-Jen C. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993, S3, 790-794.
54. Ohnishi S, Murakami T, Moriyama T, Mitamura T, Mitamura K, Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 1986, 6, 440-443.
55. Eagon PK, Francavilla A, DiLeo A, et al. Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig Dis Sei 1991, 36, 1303-1308.
56. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995, 55, 498-500.
57. Nagasue N, Kohno H, Chang YG, et al. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding liver in women. Cancer 1989, 63, 112-117.
58. Nagasue N, Yukaka H, Chang YC, Ogawa Y, Kohno H, Ito A. Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans. Cancer 1986, 57, 2162-2167.
59. Nagasue N, Yu L, Yukaka H, Kohno H. Nakamura T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact an intrahepatic recurrence after hepatic resection. Br J Surg 1995, 82, 542-547.
60. Boix L, Castells A, Bruix J, et al. Androgim receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 1995,22,616-622.
61. Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990, 65, 2641-2643.
62. Farinati F, Salvagnini M, De Maria N, el al. Unresectable hepatocellular carcinoma. A prospective controlled trial with tamoxifen. J Hepatol 1990, 11, 297-301.
63. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994, 20, 702-706.
64. Elba S, Giannuzzi V, Misciagna G, Manjjhisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. ItalJ Gastroenteml 1994, 26, 66-68.
65. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double blind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109, 917-922.
66. Perrone F. The Cancer of the Liver Italian Program (CLIP): tamoxifen vs control in the treatment of hepatocellular carcinoma (HCC) - an ongoing randomised multicentric study. Tumori, 1995, 81(Suppl.) A326, 105.
67. Gastrointestinal Tract Cancer Liaison Office booklet. Bleiberg H coordinator. EORTC, 2nd edition, 1996, 91.
68. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987, 71, 1213-1216.
69. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996, 77, 872-877.
70. Friedman MA, Demanes DJ, Hoffman PG Jr. Hepatomas: hormone receptors and therapy. Am J Med 1982, 73, 362-366.
71. Colleoni M, Nelli P, Vicario G, Mastropasqua G, Manente P. Megestrol acetate in unresectable hepatocellular carcinoma. Tumori 1995, 81, 351-353.
72. Chao Y, Chan WK, Huang YS, et al. Megace treatment of hepatocellular carcinoma. 10th World Congress of Gastroenterology, Los Angeles, September 1994, 1725.
73. Forbes A, Wilkinson ML, Iqbal MJ, Johnson PJ, Williams R. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free α-dihydrotestoster-one. Eur J Cancer Clin Oncol 1987, 23, 1659-1664.
74. Gupta S, Korula J. Failure of ketoconazole as an anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroentcrol 1988, 10, 651-654.
75. Chao Y, Chan WK, Huang YS, et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 1996, 77, 635-639.
76. Bleiberg H, Grimaldi C, Gay F, et al. Double-blind clinical trial of antiandrogen therapy vs placebo in unresectable hepatocellular carcinoma. Proc Annu Met Am Soc Clin Oncol 1993, 12, A561.
77. Falkson G, Ansell S. Phase II trial of buserelin in hepatocellular carcinoma. Eur J Cancer Clin Oncol 1989, 25, 1139-1440.
78. Guechot J, Peigney N, Ballet F, Vaubourdolle M, Giboudeau J, Poupon R. Effect of D-Tryptophan-6-luteinizing hormonereleasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients widi hepatocellular carcinoma. Hepatology 1989, 10, 346-348.
79. Manesis EK, Giannoulis G, Zoumbolis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized controlled trial. Hepatology 1995, 21, 1535-1542.
80. Roila F, Crino L, Carloni G, Natalini G. Cyproterone acetate: hepatotoxicity and prostatic cancer treatment. Ann Oncol 1993, 4, 701.